How Argenx Scaled to $4 Billion Without Bureaucracy

Biotech companies face the same dilemma as businesses in other industries: Innovation drops off dramatically with scale. European biotech Argenx has reached a market value of more than $40 billion, having so far escaped that innovation trap. How has it done this? The company shuns hierarchy and instead organizes into small teams, each dedicated to fighting a single disease with a laser focus on bringing value to the patient.

“Humans can have incredible impact when you allow them to,” said Argenx’s incoming CEO, Karen Massey.

이번 에피소드에서는 모든 레벨의 리더, she explains how the company manages to retain the nimbleness of a startup.

The Argenx Playbook: Borrow These Ideas

• Use no budgets — only plans — to keep teams focused on the right priorities.
• Stop counting layers of management and try Argenx’s alternative. Fight the urge to give quick answers and maintain curiosity as a leader.

Listen as hosts Kate W. Isaacs and Michele Zanini dig into the details of how Argenx uses distributed leadership to maintain its innovative edge and uncover insights that you can apply in your own organization.

비디오 크레딧

Karen Massey is the incoming CEO of Argenx.

케이트 W. 아이작스 MIT 슬론 경영대학원의 선임 강사입니다.

미셸 자니니 is coauthor of the 월스트리트 저널 베스트셀러 휴머니즘 (하버드 비즈니스 리뷰 프레스, 2020).

M. 숀 읽기 의 멀티미디어 편집기입니다. MIT 슬론 경영 리뷰.